chartexchange

VTVT
vTv Therapeutics Inc. Class A Common Stock
stockNASDAQ

At CloseNov 18, 2026 3:59:30 PM EST
16.51USD-4.511%(-0.78)21,717
After-hoursNov 18, 2026 4:27:30 PM EST
16.23USD-1.696%(-0.28)
Loading…
Loading…
Healthcare
Biotechnology
CEO
Stephen Holcombe
HQ
High Point, NC, USA
Previous Close
$17.29
Beta
1.39
52-Week High
$44.00 2026-01-06
52-Week Low
$16.71 2026-11-17
SMA 50
$27.42
SMA 200
$32.70
Avg. Vol 10D
24,642
Avg. Vol 30D
22,915
Avg. Vol 90D
54,206
Relative Vol
0.95
2.06M
2.8100%
111
Nov 21, 2023 · 1-for-40 (reverse)
VTVT Profile

vtv therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs. our mission is to utilize our innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines. we have a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, diabetes and metabolic disorders, inflammation and cancer.

VTVT Performance
PeriodPriceDateChangeBeta
1W21.472026-11-11-24.03%3.531
1M26.942026-10-19-39.46%2.002
3M31.482026-08-18-48.19%1.768
6M35.492026-05-18-54.04%1.370
1Y30.112025-11-18-45.83%1.391
2Y16.902024-11-18-3.49%—
5Y58.802021-11-18-72.26%0.121
VTVT Stock Summary

vTv Therapeutics Inc. Class A Common Stock (NASDAQ:VTVT) stock price today is $16.31, and today's volume is 21,717. VTVT is down 5.668% today. The 30 day average volume is 22,915. VTVT market cap is $65.43M with 4.01M shares outstanding.